Which loop diuretic is best for a patient with end‑stage renal disease (ESRD) and heart‑failure exacerbation who is currently taking oral bumetanide 2 mg twice daily?

Best Diuretic for ESRD with Heart Failure

For a patient with ESRD and heart failure exacerbation currently on oral bumetanide 2 mg twice daily, switch to intravenous bumetanide at a minimum of 2.5 times the home oral dose (10 mg IV total daily dose, divided into twice-daily dosing). 1

Route of Administration is Critical

The intravenous route is strongly preferred over oral administration during acute heart failure exacerbations, regardless of which loop diuretic is chosen. 1 This is because:

• Patients with acute HF develop intestinal edema leading to unpredictable absorption of oral diuretics, even with agents like bumetanide that have high baseline oral bioavailability 1
• The heightened RAAS/SNS activity in acute HF creates persistent sodium avidity requiring higher doses to reach the therapeutic threshold 1
• IV administration ensures reliable drug delivery and more predictable diuretic response 1

Loop Diuretic Selection in ESRD

Loop diuretics are the agents of choice in end-stage renal disease. 2 Among the available options:

Bumetanide vs. Torsemide vs. Furosemide

While bumetanide and torsemide both have superior oral bioavailability compared to furosemide, recent evidence suggests torsemide may have advantages over bumetanide in HF patients: 1, 3

• A 2025 real-world study of 16,277 matched HFrEF patients found bumetanide was associated with significantly higher all-cause mortality (19.7% vs 16.0%; OR 1.28), more hospitalizations/ED visits (53.3% vs 48.3%; OR 1.22), more acute kidney injury (33.4% vs 27.1%; OR 1.35), and more hypokalemia (16.6% vs 13.7%; OR 1.21) compared to torsemide 3
• Torsemide has preclinical and clinical data supporting favorable RAAS modulation with possible disease modification effects in HF 1

However, since this patient is already on bumetanide with established dosing, switching to IV bumetanide is reasonable for the acute exacerbation, with consideration of transitioning to torsemide after stabilization. 1, 3

Dosing Strategy for ESRD

Higher doses are required in ESRD due to pharmacokinetic changes: 2, 4

• Diminished renal clearance necessitates increased doses to achieve therapeutic effect 2
• In chronic renal failure or nephrotic syndrome, doses up to 15 mg/day bumetanide may be required 5
• Start with at least 2.5× the home oral dose when converting to IV (per HF guidelines for acute exacerbation) 1

For this patient on bumetanide 2 mg PO BID (4 mg/day total):

• Minimum IV dose: 10 mg/day divided (e.g., 5 mg IV BID) 1
• May require uptitration based on natriuretic response 1

Monitoring Diuretic Response

Use spot urine sodium at 2 hours post-dose to guide therapy rather than relying solely on urine output or daily weights: 1

• Spot urine sodium <50-70 mEq/L at 2 hours indicates inadequate diuretic response 1
• Hourly urine output <100-150 mL during first 6 hours also indicates insufficient response 1
• This allows rapid uptitration decisions rather than waiting for weight changes 1

Continuous vs. Bolus Dosing

Either continuous infusion or intermittent bolus dosing is acceptable—the DOSE trial showed no difference in outcomes between these strategies. 1 However:

• Continuous bumetanide infusion (mean 1.08 mg/hour) produces mean urine output of 1.88 mL/kg/hour 6
• AKI incidence with continuous infusion is 24.7%, with higher doses correlating with increased AKI risk 6
• Close monitoring for new-onset or worsening AKI is essential 6

Important Caveats for ESRD Patients

Diuretics in dialysis-dependent ESRD have limited but real utility: 2, 4, 7

• The increase in sodium and water excretion is very limited in anuric patients 4
• High-dose diuretics carry risks of ototoxicity (especially with concurrent aminoglycosides), neurologic lesions, cramps, deafness, weakness, and muscle pain 4, 8
• Muscle cramps are particularly common with bumetanide in renal disease patients 5
• If the patient has minimal residual urine output (<200-300 mL/day), ultrafiltration through dialysis becomes the primary volume management strategy 7

Electrolyte Monitoring

Frequent monitoring is mandatory: 8

• Check serum potassium periodically; add potassium supplements or potassium-sparing diuretics if needed 8
• Monitor other electrolytes in patients on high doses or prolonged therapy 8
• Bumetanide increases urinary calcium excretion (risk of hypocalcemia) and magnesium excretion (risk of hypomagnesemia) 8
• Hyperuricemia may occur but is typically asymptomatic 8

Ototoxicity Risk

Avoid concurrent use of aminoglycosides or other ototoxic agents with IV bumetanide, especially in ESRD. 8 Bumetanide appears to cause less audiological impairment than furosemide at equipotent doses 5, but the risk increases with:

• High doses 8
• Impaired renal function 8
• Concurrent ototoxic medications 2